During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

Bristol-Myers Squibb terminated a real-world, non-interventional study on Ozanimod, targeting moderate-to-severe ulcerative ...

Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following CD19-directed CAR-T, according to results of a phase 1 study.More than 80% ...

While current methods of isolating islet cells for transplantation strip away the structural scaffold that supports the cells ...

On Wednesday, Biokin reported (PDF) positive topline results from a phase 3 trial of the ADC. The study enrolled patients ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

Long-term follow-up data show that the preventive effects of short-term treatment with abatacept disappear after 4-5 years.

Ashish Patil stands at the forefront of this evolution, transforming logistics through innovation, decision intelligence, and ...

Bristol-Myers Squibb is running a rigorous Phase 2/3 clinical trial on ozanimod, aiming to help children with moderate to severe ulcerative colitis who haven’t responded to conventional treatments.

The stock's rise snapped a four-day losing streak.